Nicolella Valerio, Varelli Marco, Fasano Stefania, Sirica Rosa, Polito Carmela, Saviano Aniello, Fiorenza Mariano, Novarella Federica, Ranucci Davide, Carotenuto Antonio, Petracca Maria, Lanzillo Roberta, Brescia Morra Vincenzo, Castaldo Giuseppe, Terracciano Daniela, Moccia Marcello
Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy.
Istituto Diagnostico Varelli, Naples, Italy.
J Neurol. 2025 Jul 9;272(8):495. doi: 10.1007/s00415-025-13223-9.
Clinical use of neurofilament light chain (NfL) requires cut-off values that reflect disease status independently of confounding factors, such as age, hemodilution, and cardiovascular risk factors. We compared the performance of different previously suggested cut-offs in separating MS cases and controls, and in identifying different MS clinical features, across age groups.
In this cross-sectional study, we included people with MS (n = 312) and age-, sex-, and eGFR-matched controls (n = 236). For MS cases, we collected descriptor of disease progression (relapsing or progressive), EDSS, and evidence of disease activity in the previous year (including relapses, active MRI, and EDSS progression) and disease duration. Plasma NfL (pNfL) was evaluated using Lumipulse™ fully automated chemiluminescent enzyme immunoassay. We then classified both MS cases and controls based on pNfL suggested by Simrèn et al. (specific for different age ranges), Vermunt et al. (age-derived percentiles), and Benkert et al. (age- and BMI-derived percentiles).
In individuals aged 18-50 years, the three suggested pNfL cut-offs provided high specificity (> 85%) in discriminating MS cases and controls (AUC = 0.73; 95%CI = 0.67, 0.78; p = 0.028). In the MS population, the three suggested pNfL cut-offs provided high sensitivity (> 75%) in discriminating relapsing and progressive cases (AUC = 0.70; 95%CI = 0.63, 0.77; p = 0.034), patients with EDSS ≥ 4.0 and EDSS < 4.0 (AUC = 0.69; 95%CI = 0.63, 0.76; p = 0.032), and patients with EDSS ≥ 6.0 and EDSS < 6.0 (AUC = 0.70; 95%CI = 0.62, 0.78; p = 0.040). The three suggested pNfL cut-offs provided lower accuracy in age groups older than 50 years.
Previously validated cut-offs provided similar sensitivity and specificity in separating MS cases and controls and in identifying MS clinical features across different age groups, with the best performance before 50 years.
神经丝轻链(NfL)的临床应用需要截断值,该截断值能独立于年龄、血液稀释和心血管危险因素等混杂因素反映疾病状态。我们比较了之前提出的不同截断值在区分多发性硬化症(MS)病例和对照以及识别不同年龄组MS临床特征方面的表现。
在这项横断面研究中,我们纳入了MS患者(n = 312)以及年龄、性别和估算肾小球滤过率(eGFR)匹配的对照(n = 236)。对于MS病例,我们收集了疾病进展描述(复发型或进展型)、扩展残疾状态量表(EDSS)以及前一年疾病活动的证据(包括复发、MRI显示的活动情况和EDSS进展)和疾病持续时间。使用Lumipulse™全自动化学发光酶免疫分析法评估血浆NfL(pNfL)。然后,我们根据Simrèn等人提出的pNfL(针对不同年龄范围)、Vermunt等人提出的(年龄百分位数)以及Benkert等人提出的(年龄和体重指数百分位数)对MS病例和对照进行分类。
在18至50岁的个体中,三种建议的pNfL截断值在区分MS病例和对照方面具有较高的特异性(> 85%)(曲线下面积[AUC] = 0.73;95%置信区间[CI] = 0.67,0.78;p = 0.028)。在MS人群中,三种建议的pNfL截断值在区分复发型和进展型病例(AUC = 0.70;95%CI = 0.63,0.77;p = 0.034)、EDSS≥4.0和EDSS < 4.0的患者(AUC = 0.69;95%CI = 0.63,0.76;p = 0.032)以及EDSS≥6.0和EDSS < 6.0的患者(AUC = 0.70;95%CI = 0.62,0.78;p = 0.040)方面具有较高的敏感性(> 75%)。三种建议的pNfL截断值在50岁以上年龄组中的准确性较低。
先前验证的截断值在区分MS病例和对照以及识别不同年龄组的MS临床特征方面提供了相似的敏感性和特异性,在50岁之前表现最佳。